/ /

  • linkedin
  • Increase Font
  • Sharebar

    TCP gains traction as modality for glaucoma cases with good visual potential

    Refining laser delivery improves safety for procedures; allows for earlier intervention

    Take-home message: A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.


    Fairfield, CT—The typical glaucoma treatment algorithm progresses from medical therapy to laser procedures and then to traditional surgical procedures.

    Laser procedures can be used to either increase aqueous outflow, such as with laser trabeculoplasty, or decrease aqueous production, such as with cycloablative procedures.

    Just as argon laser trabeculoplasty has largely been replaced by selective laser trabeculoplasty, with lower levels of laser energy and fewer side effects, transscleral cyclophotocoagulation (TCP) is also getting a makeover.

    Cyclophotocoagulation was traditionally relegated to cases of refractory glaucoma with poor visual potential due to the risks associated with the procedure.1,2

    However, it has started to gain traction as a modality for glaucoma cases with good vision potential following refinements to the procedure, such as the use of an 810-nm laser and a transscleral approach. In a study evaluating the long-term results of TCP in eyes with ambulatory vision (6/36 or better), results showed a mean reduction of IOP of 43% and mean visual acuity preserved in the subgroups with good vision.3

    Overall complication rate in this study was 9%, including hyphema, chronic iritis, and corneal edema.

    Robert J. Noecker, MD
    Dr. Noecker, vice chair, University of Pittsburgh Medical Center Eye Center, and director, Glaucoma Service and associate professor of ...

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results